Skip to content

Nat Med

ISSN 1078-8956; 1546-170x;

6 papers in the library · 446 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Nat Med February 16, 2026 David Erritzøe, Tommaso Barba, Tiffanie Benway et al. 4 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled,...

DOI: 10.1038/s41591-025-04154-z (opens in new tab) Full text (opens in new tab)

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nat Med November 1, 2024 Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al. 4 citations

In the version of the article initially published, some members of the MAPP2 Study Collaborator Group were listed only in the Supplementary Information. Charlotte Harrison, Berra Yazar-Klosinski, Wael Garas, Darrick May, Cole Marta, Susan Walker, Elizabeth Nielson, Gregory Wells, Randall Brown, Revital Amiaz, Yair Wallach, Ray Worthy, Alia Lilienstein and Amy Emerson have now been added to the...

DOI: 10.1038/s41591-024-03331-w (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psychedelic-assisted psychotherapy PTSD Treatment Trauma therapy +26

Increased global integration in the brain after psilocybin therapy for depression.

Nat Med April 11, 2022 Richard E. Daws, Christopher Timmermann, Bruna Giribaldi et al. 432 citations

Psilocybin therapy shows antidepressant potential, but its therapeutic actions are not well understood. We assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI)...

DOI: 10.1038/s41591-022-01744-z (opens in new tab) Magic mushrooms Psychedelic-assisted therapy Major depressive disorder Brain plasticity +23